

UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER OF PATENTS AND TRADEMARKS P.O. Box 1450 Alexandria, Viginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.	
09/826,025	04/04/2001	Lung-Ji Chang	CNG-100D1 4500		
7	06/03/2003				
OPPENHEIMER WOLFF & DONNELLY LLP 840 NEWPORT CENTER DRIVE, SUITE 700 NEWPORT BEACH, CA 92660			EXAMINER		
			FALK, ANNE MARIE		
			ART UNIT	PAPER NUMBER	
			1632	1)	
			DATE MAILED: 06/03/2003		

Please find below and/or attached an Office communication concerning this application or proceeding.

				File		
		Appl	ication No.	Applicant(s)		
Office Action Summary		09/8	26,025	CHANG, LUNG-JI		
		Exar	niner	Art Unit		
		Anne	-Marie Falk, Ph.D.	1632		
P riod fo	The MAILING DATE of this commu	nication appears o	n the cover sheet with the	correspondence address		
A SHO THE N - Exten after: - If the - If NO - Failur	ORTENED STATUTORY PERIOD F MAILING DATE OF THIS COMMUN asions of time may be available under the provision SIX (6) MONTHS from the mailing date of this com period for reply specified above is less than thirty (period for reply is specified above, the maximum s re to reply within the set or extended period for reply	IICATION. s of 37 CFR 1.136(a). In munication. 30) days, a reply within tl tatutory period will apply y will, by statute, cause tl	no event, however, may a reply be to the statutory minimum of thirty (30) do and will expire SIX (6) MONTHS from the application to become ABANDON	timely filed ays will be considered timely. m the mailing date of this communication. IED (35 U.S.C. § 133).		
earne Status	eply received by the Office later than three months d patent term adjustment. See 37 CFR 1.704(b).	arter the maining date or	inis communication, even il timely in	su, may reduce any		
1)⊠	Responsive to communication(s) f	iled on <u>25 <i>March</i></u>	<u> 2003</u> .			
2a) <u></u>	This action is FINAL.	2b)⊠ This action	on is non-final.			
3) Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under <i>Ex parte Quayle</i> , 1935 C.D. 11, 453 O.G. 213. Disp sition of Claims						
4)⊠	Claim(s) 17-50 is/are pending in th	e application.				
4	4a) Of the above claim(s) 17-20 and 29-50 is/are withdrawn from consideration.					
5) Claim(s) is/are allowed.						
6)⊠	6)⊠ Claim(s) <u>21-28</u> is/are rejected.					
7) Claim(s) is/are objected to.						
8) Claim(s) are subject to restriction and/or election requirement.						
Application	on Papers					
9)[] 7	The specification is objected to by th	e Examiner.				
10)□ 1	The drawing(s) filed on is/are	a)□ accepted or	b)⊡ objected to by the Ex a	aminer.		
	Applicant may not request that any ob	-				
11) 🔲 T	The proposed drawing correction file	ed on is: a)	☐ approved b)☐ disappr	oved by the Examiner.		
	If approved, corrected drawings are re	equired in reply to th	is Office action.			
12) 🗌 T	The oath or declaration is objected to	by the Examine	r.			
Priority u	nder 35 U.S.C. §§ 119 and 120					
13)	Acknowledgment is made of a claim	n for foreign priori	ty under 35 U.S.C. § 119(a)-(d) or (f).		
a) ☐ All b) ☐ Some * c) ☐ None of:						
	1. Certified copies of the priority documents have been received.					
	2. Certified copies of the priority documents have been received in Application No					
	 Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)). * See the attached detailed Office action for a list of the certified copies not received. 					
_			•			
	cknowledgment is made of a claim to		•			
	The translation of the foreign landschowledgment is made of a claim		* *			
Attachment	(s)					
	e of References Cited (PTO-892) e of Draftsperson's Patent Drawing Review (F nation Disclosure Statement(s) (PTO-1449) F			ry (PTO-413) Paper No(s) Patent Application (PTO-152)		
	iation Disclosure Statement(s) (F10-1449) F	aper 110(3)	о) <u>—</u> опист			

Application/Control Number: 09/826,025

Art Unit: 1632

DETAILED ACTION

The response filed March 25, 2003 (Paper No. 9) has been entered. Applicants' election of Group II, Claims 21-28 in Paper No. 9 is acknowledged. Because applicant did not distinctly and specifically point out the supposed errors in the restriction requirement, the election has been treated as an election without traverse (MPEP § 818.03(a)). The elected invention is drawn to an expression vector.

Claims 17-50 are pending in the instant application.

Claims 17-20 and 29-50 are withdrawn from further consideration pursuant to 37 CFR 1.142(b) as being drawn to a nonelected invention. Election was made without traverse in Paper No. 9.

Claims 21-28 are examined herein.

Claim Rejections - 35 USC § 112

The following is a quotation of the first paragraph of 35 U.S.C. 112:

The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same and shall set forth the best mode contemplated by the inventor of carrying out his invention.

Claims 21-28 are rejected under 35 U.S.C. 112, first paragraph, as containing subject matter which was not described in the specification in such a way as to reasonably convey to one skilled in the art that the inventors, at the time the application was filed, had possession of the claimed invention.

Applicants are referred to the final guidelines on written description published January 5, 2001 in the Federal Register at Volume 66, Number 4, pp. 1099-1111 (also available at www.uspto.gov).

The claims recite a functional fragment of a B7-2 protein or a functional fragment of an immune modulating protein. However, the specification does not provide a written description of functional fragments of a B7-2 protein or functional fragments of an immune modulating protein. The specification does not clearly define the intended scope of the phrase "functional fragment" and it is unclear what

Application/Control Number: 09/826,025

Art Unit: 1632

particular function is being referred to. In the absence of a clear definition, the phrase encompasses a wide variety of fragments and there is no requirement that any essential part of the reference molecule remain as part of the "functional fragment." In analyzing whether the written description requirement is met for genus claims, it is first determined whether a representative number of species have been described by their complete structure. In the instant case, only a single embodiment, i.e. the B7-2 protein or the full-length immune modulating protein, is described by its complete structure. Next then, it is determined whether a representative number of species have been sufficiently described by other relevant identifying characteristics. In this case, the specification does not describe functional fragments by other relevant identifying characteristics. Furthermore, there is no requirement that any essential part of the reference protein remain as part of the "functional fragment." This limited information is not deemed sufficient to reasonably convey to one skilled in the art that Applicants were in possession of functional fragments as recited in the claims, at the time the application was filed. Thus, it is concluded that the written description requirement is not met for the claimed genus of functional fragments.

Conclusion

No claims are allowed.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Anne-Marie Falk, Ph.D. whose telephone number is (703) 306-9155. The examiner can normally be reached Monday through Thursday and alternate Fridays from 10:00 AM to 7:30 PM.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Deborah Reynolds, can be reached on (703) 305-4051. The fax phone number for the organization where this application or proceeding is assigned is (703) 308-8724.

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the patent analyst, William Phillips, whose telephone number is (703) 305-3482.

Anne-Marie Falk, Ph.D.

Anne-Marie Falk, PH.D
PRIMARY EXAMINER